Efficacy and safety of triple therapy versus dual therapy for lymphatic filariasis: A systematic review and meta-analysis.
albendazole
diethylcarbamazine
dual therapy
ivermectin
lymphatic filariasis
meta-analysis
systematic review
triple therapy
Journal
Tropical medicine & international health : TM & IH
ISSN: 1365-3156
Titre abrégé: Trop Med Int Health
Pays: England
ID NLM: 9610576
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
pubmed:
27
1
2022
medline:
4
5
2022
entrez:
26
1
2022
Statut:
ppublish
Résumé
Lymphatic filariasis is a serious public health issue. Recent studies showed that a single dosage of triple therapy (Ivermectin, Diethylcarbamazepine, and Albendazole) is more effective than dual therapy (Ivermectin plus Albendazole or Diethylcarbamazepine plus Albendazole) for clearing microfilaria from the blood. We aimed to evaluate the efficacy and safety of triple therapy versus dual therapy in patients infected with microfilaria and communities endemic to lymphatic filariasis. For this systematic review and meta-analysis, we searched MEDLINE, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials, and Web of Science until 24th June 2021. We included randomized control trials that compared triple with dual therapy given to patients with lymphatic filariasis or endemic communities. This study was registered with PROSPERO (CRD42021266724). We included eight articles after the screening process. Triple therapy caused more clearance of microfilaria in the blood (RR: 1.52; 95% CI: 1.15, 2.02; p = 0.003), while dual therapy caused more clearance of the circulating filariae antigen in the blood (RR: 0.76; 95% CI: 0.65, 0.88; p = 0.0003), both 12 months after drug administration. The triple therapy had a similar adverse effect compared with the dual therapy group. Based on the greater efficacy in the clearance of microfilaria and the safety of triple therapy, it constitutes a better strategy for the eradication programs of lymphatic filariasis in endemic regions. However, further studies are needed to confirm our results.
Substances chimiques
Filaricides
0
Ivermectin
70288-86-7
Albendazole
F4216019LN
Diethylcarbamazine
V867Q8X3ZD
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
226-235Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Utzinger J, Becker SL, Knopp S, Blum J, Neumayr AL, Keiser J, et al. Neglected tropical diseases: diagnosis, clinical management, treatment and control. Swiss Med Wkly. 2012;142:47.
Global programme to eliminate lymphatic filariasis: progress report, 2017 [Internet]. [cited 2021 Aug 30]. Available from: https://www.who.int/publications/i/item/who-wer9344-589-602
WHO. Global programme to eliminate lymphatic filariasis: progress report, 2019 [Internet]. [cited 2021 Aug 2]. Available from: https://www.who.int/publications/i/item/who-wer9543
Ottesen EA, Duke BO, Karam M, Behbehani K. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ. 1997;75(6):491.
Partono F. Filariasis in indonesia: clinical manifestations and basic concepts of treatment and control. Trans Royal Soc Tropical Med Hygiene. 1984;78(1):9-12.
WHO. Global programme to eliminate lymphatic filariasis: progress report, 2018 [Internet]. [cited 2021 Aug 2]. Available from: https://www.WHO.int/publications/i/item/who-wer9441-457-472
de Silva N, Guyatt H, Anthelmintics BD. Anthelmintics. Drugs. 1997;53(5):769-88. https://doi.org/10.2165/00003495-199753050-00004
Ottesen EA, Hooper PJ, Bradley M, Biswas G. The Global Programme to Eliminate Lymphatic Filariasis: Health Impact after 8 Years. PLoS Negl Trop Dis. 2008;2(10):e317.
Bockarie MJ, Tisch DJ, Kastens W, Alexander NDE, Dimber Z, Bockarie F, et al. Mass Treatment to Eliminate Filariasis in Papua New Guinea. N Engl J Med. 2002;347(23):1841-8.
Farid HA, Hammad RE, Hassan MM, Ramzy RMR, El Setouhy M, Weil GJ. Effects of combined diethylcarbamazine and albendazole treatment of bancroftian filariasis on parasite uptake and development in Culex pipiens L. Am J Trop Med Hyg. 2005;73(1):108-14.
Ismail MM, Jayakody RL, Weil GJ, Fernando D, De Silva MS, De Silva GA, et al. Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg. 2001;95(3):332-5.
Tisch DJ, Michael E, Kazura JW. Mass chemotherapy options to control lymphatic filariasis: a systematic review. Lancet Infect Dis. 2005;5(8):514-23.
World Health Organization. Weekly Epidemiological Record, 23 October 2020. Wkly Epidemiol Rec. 2020;95(43):509-24.
World Health Organization. Progress report 2000-2009 and strategic plan 2010-2020 of the global programme to eliminate lymphatic filariasis: halfway towards eliminating lymphatic filariasis. Geneva PP - Geneva: World Health Organization;
World Health Organization. World Health Organization. Global programme to eliminate lymphatic filariasis: progress report, 2018. Wkly Epidemiol Rec. 2019;94(41):457-72.
Thomsen EK, Sanuku N, Baea M, Satofan S, Maki E, Lombore B, et al. Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis. Clin Infect Dis. 2016;62(3):334-41.
Weil GJ, Bogus J, Christian M, Dubray C, Djuardi Y, Fischer PU. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study. PLoS Medicine. 2019;16(6):e1002839.
King CL, Suamani J, Sanuku N, Cheng Y-C, Satofan S, Mancuso B, et al. A Trial of a Triple-Drug Treatment for Lymphatic Filariasis. N Engl J Med. 2018;379(19):1801-10.
World Health Organization (WHO). Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis. Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis. 2017.
Irvine MA, Stolk WA, Smith ME, Subramanian S, Singh BK, Weil GJ, et al. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study. Lancet Infect Dis. 2017;17(4):451-8.
Budge PJ, Herbert C, Andersen BJ, Weil GJ. Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature. PLoS Negl Trop Dis. 2018;12(5):e0006454.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29:372.
Innovation VH. Covidence systematic review software [Internet]. Melbourne, Australia; Available from: http://www.covidence.org/
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2011 Oct 18 [cited 2021 Jul 22];343(7829). Available from: https://www.bmj.com/content/343/bmj.d5928
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. Rating Quality of Evidence and Strength of Recommendations: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ Br Med J. 2008;336(7650):924-6.
Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. Rating Quality of Evidence and Strength of Recommendations: What is “quality of evidence” and why is it important to clinicians? BMJ Br Med J. 2008;336(7651):995-8.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ Br Med J. 2003;327(7414):557-60.
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-34.
RevMan | Cochrane Training [Internet]. [cited 2021 Aug 3]. Available from: https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman
Hardy M, Samuela J, Kama M, Tuicakau M, Romani L, Whitfeld MJ,. et al. 2020;14(3):e0008106.
Dubray CL, Sircar AD, de Rochars VMB, Bogus J, Direny AN, Ernest JR, et al. Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study. PLOS Neg Tropical Dis. 2020;14(6):1-21.
Jambulingam P, Kuttiatt VS, Krishnamoorthy K, Subramanian S, Srividya A, Raju HKK, et al. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India. PLOS Negl Trop Dis. 2021;15(2):1-26
Hardy M, Samuela J, Kama M, Tuicakau M, Romani L, Whitfeld MJ, et al. Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial. Clin Infect Dis. 2021;17:30.
Supali T, Djuardi Y, Christian M, Iskandar E, Alfian R, Maylasari R. An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia. PLOS Negl Trop Dis. 2021;15(3):e0009294
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4:89.
Yajima A, Ichimori K. Progress in the elimination of lymphatic filariasis in the Western Pacific Region: successes and challenges. International Health. 2020;13(Supplement_1):S10-6.
Weil GJ, Bogus J, Christian M, Dubray C, Djuardi Y, Fischer PU, et al. The safety of double-and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study. PLoS Medicine. 2019;16(6):e1002839.
Molyneux DH. The London Declaration on Neglected Tropical Diseases: 5 years on. Trans R Soc Trop Med Hyg. 2016;110(11):623-5.
Transforming our world: the 2030 Agenda for Sustainable Development | Department of Economic and Social Affairs [Internet]. [cited 2021 Aug 2]. Available from: https://sdgs.un.org/2030agenda
Hotez PJ, Damania A, Barua A, Stanaway J. The first “London Declaration”: The Commonwealth and its neglected tropical diseases. PLoS Negl Trop Dis. 2017;11(4):e0005321.
Ga W, Hj M. A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018. PLoS Negl Trop Dis. 2020;14(11):e0008854.
Doestzada M, Vila AV, Zhernakova A, Koonen DPY, Weersma RK, Touw DJ, et al. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein & Cell. 2018;9(5):432-45. https://doi.org/10.1007/s13238-018-0547-2
Bjerum CM, Ouattara AF, Aboulaye M, Kouadio O, Marius VK, Andersen BJ, et al. Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d’Ivoire: An Open-label Randomized Controlled Trial. Clin Infect Dis. 2020;71(7):e68-75.
Weil GJ, Jacobson JA, King JD. A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery. International Health. 2020;13(Supplement_1):S60-4
Helmy H, Weil GJ, Ellethy AST, Ahmed ES, El SM, Ramzy RMR. Bancroftian filariasis: effect of repeated treatment with diethylcarbamazine and albendazole on microfilaraemia, antigenaemia and antifilarial antibodies. Trans R Soc Trop Med Hyg. 2006;100(7):656-62.
Hussein O, Setouhy EL, Ahmed ES, Kandil AM, Ramzy RMR, Helmy H, et al. Duplex doppler sonographic assessment of the effects of diethylcarbamazine and albendazole therapy on adult filarial worms and adjacent host tissues in bancroftian filariasis. Am J Tropical Med Hygiene. 2004;71(4):471-7.
Ivermectin GTG. Ivermectin 20 years on: maturation of a wonder drug. Trends Parasitol. 2005;21(11):530-2. https://doi.org/10.1016/j.pt.2005.08.014
Budge PJ, Herbert C, Andersen BJ, Weil GJ. Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature. PLoS Negl Trop Dis. 2018;12(5):e0006454.
King CL, Weil GJ, Kazura JW. Single-Dose Triple-Drug Therapy for Wuchereria bancrofti - 5-Year Follow-up. NEJMC. 2020;382(20):1956-7.
Macfarlane CL, Budhathoki SS, Johnson S, Richardson M, Garner P. Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis. Cochrane Database Syst Rev. 2019;2019(1):58.